EATONTOWN, N.J., Nov. 27 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Nasdaq: RPCX) notes that it is not aware of any specific reason
to account for the current decline in the price of the Company's common stock.
Roberts financial health is strong with over $100 million in cash.
Additionally, several recent developments portend significant strengthening in
Roberts long-term fundamentals and growth outlook.
    ProAmatine(R), the first of Roberts pipeline drugs, recently began
shipping into the marketplace and sales are expected to ramp up during 1997.
Agrelin(R), the second pipeline product, is currently undergoing labeling
review, typically the last step in the FDA approval process.  Additionally,
the Company enriched its pipeline potential by licensing compounds for
development as possible breakthrough drugs for large, unsatisfied
gastrointestinal markets. Furthermore, through the use of a comparatively
small portion of its cash, Roberts plans to purchase a manufacturing facility
that is expected to eventually result in substantial savings in the cost of
sales.
    Roberts Pharmaceutical Corporation is an international pharmaceutical
company focusing on the acquisition and development of late-stage drugs.
Roberts currently markets its products in seven countries and has operating
subsidiaries in the U.S., Canada, and the United Kingdom.

    This release contains forward-looking statements which reflect
management's current views of future events and operations.  These forward-
looking statements are based on assumptions and external factors, including
assumptions relating to regulatory action and competing products.  Any changes
in such assumptions or external factors could produce significantly different
results.

Link to this page: